Soy in hypercholesterolaemia: a double-blind, placebo-controlled trial
| Autor: | Pekka Puska, V Korpelainen, Eva Skovlund, L H Høie, K T Smerud, T Lahti |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Hypercholesterolemia Placebo-controlled study Medicine (miscellaneous) Placebo law.invention Double blind chemistry.chemical_compound Randomized controlled trial Double-Blind Method law Internal medicine medicine Humans Soy protein Finland Aged Nutrition and Dietetics Cholesterol business.industry Cholesterol LDL Isoflavones Middle Aged Surgery Clinical trial chemistry Soybean Proteins Female business |
| Zdroj: | European journal of clinical nutrition. 56(4) |
| ISSN: | 0954-3007 |
| Popis: | Objective: To study whether Abacor®, a product based on isolated soy protein with high and standardised levels of isoflavones and cotyledon soy fibres, was more effective in lowering total and LDL cholesterol than placebo. Design: Randomised, placebo-controlled, double-blind, parallel group, single centre study. Setting: Primary care in Joensuu, North Karelia, Finland. Subjects: Subjects were screened from the patient database of the health centre; 30 were randomised to the Abacor® group and 30 subjects to placebo. Eight subjects were withdrawn, six from the active group, two from the placebo group. Intervention: The preparations were given as two daily liquid supplements in addition to the subjects' regular diets for 6 weeks. Results: Abacor® showed a statistically significant lipid-lowering effect as compared to placebo, although an unexpected reduction was seen in the placebo group. The estimated difference between active treatment and placebo was 0.25 mmol/l (95% CI 0.01, 0.50; P=0.049) for total cholesterol, corresponding to reductions of 8.3 and 5.1%, respectively. The difference in reduction of LDL-cholesterol was 0.27 mmol/l (95% CI 0.06, 0.49; P=0.014) and corresponded to a reduction of 13.2% in the active treatment group, and 8.0% in the placebo group. Abacor® showed a rapid onset of effect, as compared with placebo. During a wash-out period of 4 weeks after treatment, the subjects returned to pre-treatment cholesterol levels. Conclusion: Added to a regular diet, Abacor® significantly reduced LDL-cholesterol and total cholesterol. These beneficial effects occurred within 6 weeks of treatment. Sponsorship: Commercial organisation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|